NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.775
+0.015 (0.85%)
Aug 21, 2026, 10:51 AM EDT - Market open
NervGen Pharma Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 86.79 | 22.07 | 17.27 | 11.66 | 22.45 | 16.93 |
Cash & Short-Term Investments | 86.79 | 22.07 | 17.27 | 11.66 | 22.45 | 16.93 |
Cash Growth | 453.70% | 27.81% | 48.10% | -48.07% | 32.62% | 202.38% |
Accounts Receivable | - | 0.01 | 0.1 | - | - | - |
Other Receivables | 0.2 | 0.08 | 0.42 | 0.25 | 0.03 | 0.06 |
Receivables | 0.2 | 0.09 | 0.51 | 0.25 | 0.03 | 0.06 |
Prepaid Expenses | 2.7 | 0.39 | 0.29 | 0.11 | 0.08 | 0.07 |
Other Current Assets | 0.12 | 0.25 | 0.94 | 0.5 | 0.59 | 0.36 |
Total Current Assets | 89.81 | 22.8 | 19.01 | 12.52 | 23.15 | 17.42 |
Property, Plant & Equipment | - | - | - | 0.2 | 0.3 | 0 |
Other Intangible Assets | 0.38 | 0.41 | 0.46 | 0.52 | 0.43 | 0.47 |
Long-Term Accounts Receivable | - | - | 0.01 | - | - | - |
Total Assets | 90.19 | 23.21 | 19.49 | 13.24 | 23.88 | 17.9 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.29 | 0.03 | 0.03 | 3.32 | 2 | 0.35 |
Accrued Expenses | - | 4.63 | 4.91 | - | 1.4 | 0.73 |
Current Portion of Leases | - | 0.01 | 0.1 | 0.09 | 0.09 | - |
Other Current Liabilities | 68.63 | 15.07 | 11.86 | 11.73 | 6.73 | - |
Total Current Liabilities | 72.91 | 19.73 | 16.9 | 15.14 | 10.22 | 1.08 |
Long-Term Leases | - | - | 0.01 | 0.11 | 0.2 | - |
Total Liabilities | 72.91 | 19.73 | 16.91 | 15.25 | 10.41 | 1.08 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 149.86 | 103 | 81.19 | 58.93 | 57.41 | 42.4 |
Retained Earnings | -177.66 | -146.76 | -102.65 | -78.15 | -55.77 | -35.05 |
Comprehensive Income & Other | 45.07 | 47.24 | 24.03 | 17.21 | 11.82 | 9.46 |
Shareholders' Equity | 17.28 | 3.48 | 2.58 | -2.01 | 13.46 | 16.82 |
Total Liabilities & Equity | 90.19 | 23.21 | 19.49 | 13.24 | 23.88 | 17.9 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 0.01 | 0.11 | 0.2 | 0.28 | - |
Net Cash (Debt) | 86.79 | 22.06 | 17.16 | 11.46 | 22.17 | 16.93 |
Net Cash Growth | 455.74% | 28.55% | 49.72% | -48.29% | 30.95% | 202.38% |
Net Cash Per Share | 1.09 | 0.30 | 0.25 | 0.19 | 0.42 | 0.43 |
Filing Date Shares Outstanding | 92.44 | 80.93 | 70.99 | 69.93 | 59.13 | 46.23 |
Total Common Shares Outstanding | 92.44 | 79.65 | 70.33 | 59.61 | 58.78 | 46.19 |
Working Capital | 16.9 | 3.07 | 2.11 | -2.62 | 12.93 | 16.34 |
Book Value Per Share | 0.19 | 0.04 | 0.04 | -0.03 | 0.23 | 0.36 |
Tangible Book Value | 16.9 | 3.07 | 2.11 | -2.53 | 13.03 | 16.35 |
Tangible Book Value Per Share | 0.18 | 0.04 | 0.03 | -0.04 | 0.22 | 0.35 |